Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 15/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183304 | 0.89 | FASN (0.56) | FASNL3MBTL1CA12CA1CA2 | |
| SCHEMBL4167169 | 0.87 | FASN (0.59) | FASNCA12CA1CA2CA7 | |
| SCHEMBL4176216 | 0.85 | FASN (0.57) | FASN | |
| SCHEMBL4181148 | 0.85 | CA12 (0.59) | FASNCA12CA1CA2CA7 | |
| SCHEMBL4184616 | 0.85 | FASN (0.61) | FASN | |
| SCHEMBL4170791 | 0.84 | FASN (0.60) | FASN | |
| SCHEMBL4176863 | 0.84 | FASN (0.55) | FASN | |
| SCHEMBL4184710 | 0.84 | FASN (0.55) | FASNL3MBTL1CA12CA1CA2 | |
| SCHEMBL4179408 | 0.83 | FASN (0.59) | FASN | |
| SCHEMBL4169865 | 0.83 | FASN (0.59) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| WO-2008075070-A1 | SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | FASN 3/4885L3MBTL1 4658/4885CA12 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.